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Abstract: Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice. 
The understanding of the pathophysiology of AF has changed during the last several decades, 
and a significant role of inflammation and of the renin–angiotensin–aldosterone system has been 
postulated both experimentally and clinically. There is emerging evidence of an association 
between inflammation and AF, and mounting evidence links increased C-reactive protein levels 
not only to already existing AF but also to the risk of developing future AF. The beneficial effects 
of statins on AF have been reported in several studies. Several randomized clinical and large 
observational studies have shown similar result that show the beneficial effect of statins in AF. In 
clinical studies, statins were considered effective in preventing AF after electrical cardioversion, 
post-ablation, and after permanent pacemaker and implantable cardioverter defibrillator insertion. 
The antiarrhythmic mechanisms of statins regarding AF prevention in patients with heart failure are 
still not clear. Perioperative statin use has been associated with favorable postoperative outcome 
in both cardiovascular and noncardiovascular conditions. Despite a growing body of evidence that 
drugs with anti-inflammatory properties such as statins may prevent AF, the observed positive 
effects of statins on the burden of AF appeared to be independent of their cholesterol-reducing 
properties. However, further data from large-scale randomized trials are clearly needed.
Keywords: statins, pleiotropic effects, atrial fibrillation
Introduction
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice. 
The prevalence of AF is constantly increasing and affects not only the elderly, but 
also younger patient groups. AF is associated with increased morbidity and mortality, 
mostly due to stroke and heart failure. Maintaining sinus rhythm in AF patients is a 
difficult task, and in many cases the therapeutic goal lies in postponing permanent AF 
as long as possible. The vast majority of therapeutic approaches have been focused 
on the electrical problem of AF. Recently, there is increasing evidence indicating that 
AF is associated with inflammation.1–4
The understanding of the pathophysiology of AF has changed a lot during recent 
decades. A significant role of inflammation and of the renin–angiotensin system has 
been postulated experimentally and clinically.5–7
Inflammation (documented by higher levels of C-reactive protein [CRP]) appears to 
be involved in the early phase of electrical remodeling (even within 24 hours after AF 
initiation) and promotes persistence of AF. While inflammation may be a pathogenetic 
component of AF, the clinical role for anti-inflammatory drugs still remains unclear. 
Statins have been proven to be potent anti-inflammatory agents.8–10Vascular Health and Risk Management 2009:5 534
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In clinical studies, statins were considered effective in 
preventing AF after electrical cardioversion, after cardiac 
surgery, in patients with coronary artery disease (CAD), 
and in patients with left ventricular dysfunction. It would 
thus seem intuitive to suppose that if AF is indeed linked 
to inflammation, then statins would offer a potentially pre-
ventative role in AF. Therefore statin therapy may provide 
an effective treatment strategy for AF because of its potent 
anti-inflammatory and antioxidant properties.11–13
A systematic search in PubMed was done using the 
keywords ‘atrial fibrillation’, ‘statins’, and ‘inflammation’. 
All the recent studies and meta-analysis in English and the 
abstract of non-English papers were collected, analyzed, and 
summarized in this review in our attempt to reach a conclu-
sion on the role of inflammation and statins in AF.
Atrial fibrillation at the cellular level
The structural changes of the atria that define structural 
remodeling in AF include left atrial dilatation and increasing 
atrial fibrosis occurs in parallel with the changes of electrical 
remodelling. Key to this fibrotic process is the deposition of 
increased amounts of connective tissue between individual 
cells and with the deposition of large amounts of collagen 
and fibronectin. This leads to separation of myocytes from 
one another and subsequent impairment of atrial conduction 
at the cellular level. All the above culminates in alterations 
in the biophysical properties of atrial tissue, allowing the 
initiation and perpetuation of AF.14–18
Results of atrial biopsies taken from patients in AF com-
pared with controls have demonstrated evidence of inflamma-
tory infiltrates and oxidative damage within the atrial tissue. 
In one study, abnormal atrial histology was uniformly found 
in multiple biopsy specimens of 12 patients with lone AF, 
compared with normal histology in all of the controls, with 
66% of the AF group showing evidence of occult myocarditis. 
This strongly support the view that inflammation acts as an 
initiator rather than as a result of AF.19
Recently, activation of the local renin–angiotensin 
system and mitogen-activated protein kinase pathways in 
atrial myocardium has been found to play an important 
role in atrial structural remodeling related to AF. Another 
important mediator of the angiotensin II (Ang II) effect is the 
Janus kinase/signal transducers and activators of transcrip-
tion (STAT) pathway, which has never been characterized 
in the atrium. In cultured atrial myocytes and fibroblasts, 
Ang II induced tyrosine phosphorylation of STAT3 through 
a Rac1-dependent mechanism, which was inhibited by 
dominant-negative Rac1, losartan, and simvastatin. In atrial 
myocytes, activation of STAT3 by Rac1 was mediated by 
direct association of Rac1 with STAT3; however, in atrial 
fibroblasts, it was mediated by an indirect paracrine effect. 
Constitutively active STAT3 increased protein synthesis, and 
dominant-negative STAT3 abrogated Ang II-induced protein 
synthesis in atrial myocytes and fibroblasts. Rats infused long 
term with Ang II exhibited higher levels of activated Rac1, 
phospho-STAT3, collagen synthesis, and atrial fibrosis in 
the atria, all of which were attenuated by oral losartan and 
simvastatin. In human atrial tissues from patients with AF, 
Ang II and phospho-STAT3 levels were also elevated. The 
Ang II/Rac1/STAT3 pathway is an important signaling 
pathway in the atrial myocardium to mediate atrial structural 
remodeling, and losartan and statin may be able to reverse 
Ang II-induced atrial structural remodeling in AF.20
Chronic AF acutely upregulates CD40 expression as well 
as platelet adhesion to the endocardium. Simvastatin is effec-
tive in modulating this expression, thus it may potentially 
contribute to reduction of the risk of intra-atrial thrombus 
formation. This issue has been explored in experiments on 
right atrial segments obtained before the onset of cardio-
pulmonary bypass, in either presence or absence of 5 µM 
simvastatin. AF was associated with a significant increase 
of endocardial CD40 expression (293.1 ± 55.1 pg/ml vs. 
230.9 ± 53.3 pg/ml; p  0.01), and platelet–endocardial 
adhesion compared with sinus rhythm atria (10.8 ± 2.2 vs. 
5.2 ± 1.3 platelet CD41 AU; p  0.01). At immunofluores-
cence, about 62% of fibrillating endocardium was covered by 
platelets, compared with 12% of sinus rhythm atria. Addition 
of simvastatin significantly reduced CD40 expression as well 
as platelet adhesion to fibrillating atria. Its efficacy was not 
reversed by the addition of mevalonic acid.21
AF has been associated with myocardial oxidative stress, 
and antioxidant agents have demonstrated antiarrhythmic 
benefit in humans (Figure 1). Serum markers of oxidative 
stress and inflammation were compared in a cross-sectional, 
case-control design study22 of 40 male individuals, with or 
without persistent or permanent AF, who were matched for 
age, sex, diabetes, and smoking status, known confounding 
variables for the measurement of oxidative stress. (used 
derivatives of reactive oxidative metabolites [DROMs] and 
ratios of oxidized to reduced glutathione [E(h) GSH] and 
cysteine [E(h) CySH] to quantify oxidative stress). Inflam-
matory markers, including high-sensitivity CRP (hs-CRP), 
interleukins-1β (IL-1β) and -6, and tumor necrosis factor-α 
(TNF-α) were also measured. Univariate, conditional logisti-
cal regression analysis showed that oxidative stress but not 
inflammatory markers were statistically associated with Vascular Health and Risk Management 2009:5 535
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AF (p  0.05). The increase in the odds ratio (OR) for 
AF for E(h) GSH, E(h) CySH, and DROMs were 6.1 (95% 
confidence intervals [CI], 1.3–28.3; p = 0.02), 13.6 (95% CI: 
2.5–74.1; p = 0.01), and 15.9 (95% CI: 1.7–153.9; p = 0.02), 
respectively. There was a stronger correlation between E (h) 
GSH and E (h) CySH (r = 0.66) than between E(h) GSH and 
DROMs (r = 0.41). In multivariate analysis corrected for 
statins and other AF risk factors this association of AF and 
oxidative stress remained significant.
Atrial fibrillation and inflammation
Historical evidence to support an association between AF and 
inflammation can be extracted from the frequent association 
of AF with inflammatory conditions of the heart, such as 
myocarditis and pericarditis.23,24
Bruins and colleagues25 were the first to propose the 
inflammation–AF hypothesis, following their observations 
of an increased frequency of AF after coronary artery bypass 
surgery. They noted that the peak incidence of AF occurred 
on the second and third postoperative days, which coincided 
with the peak elevation of CRP levels. In an interesting study 
by Maixent and colleagues,26 the authors demonstrated the 
presence of circulating autoantibodies against myosin heavy 
chain in a significant percentage of patients with idiopathic par-
oxysmal AF, which raises the possibility of an inflammatory 
autoimmune process in some patients with paroxysmal AF.
CRP, a biomarker of inflammation, has been reported to 
be elevated in some patients with AF. Statins may prevent AF 
through anti-inflammatory and/or antioxidant effects.2,3,27–31 
The precise mechanism for the increased circulating hs-CRP 
in AF is uncertain, but might reflect active participation of 
CRP in the local inflammatory response within the atrial 
myocardium. In patients with AF, CRP may localize in atrial 
tissue, possibly binding to the membranes of myocardial cells 
in inflamed tissues and activating complement, leading to 
tissue damage.32,33 Levels of hs-CRP have been noted to be 
higher among patients with AF compared with controls in 
sinus rhythm.3,27,34–39 Also, persistent AF patients have higher 
hs-CRP levels than paroxysmal AF patients, and both have 
higher levels than controls.27 In one study, the combination 
of microalbuminuria and an elevated hs-CRP increased the 
risk of subsequent AF development by up to four-fold.40 
Furthermore, a longer duration of AF is associated with higher 
hs-CRP levels and larger left atrial dimensions, supporting a 
link between the burden of AF, inflammation, and structural 
remodeling.41 In both cross sectional and longitudinal studies, 
hs-CRP has remained a consistent and significant predictor 
of early AF relapse after successful cardioversion, even after 
adjustment for risk factors for AF, such as hypertension and 
CAD.29,34,36,41,43 hs-CRP has also been shown to be predictive 
of subsequent future development of new cases of AF among 
a large cohort of patients in sinus rhythm.3 Ablation induces 
an acute inflammatory upregulation reflected by an increase 
of CRP and fibrinogen levels and of the leukocyte count. 
The observed inflammatory response is consistent with his-
topathologic information on ablation-induced inflammatory 
activation and is supposed to contribute to the phenomenon of 
early AF recurrence.44 Although it is not yet known whether 
inflammation acts as initiator or is just a consequence of AF, 
there is evidence that CRP-lowering therapies could prevent 
 Pleiotropic effect of statins   ↔   Atrial fibrillation at cellular level 
▼ ▼
Increased nitric oxide bioavailability ↔   Activation of local renin–angiotensin system 
Improve sympathetic-vagal balance ↔   Abnormal vagal tone 
Improve endothelial dysfunction     ↔   Upregulates CD40 expression  
Inhibit inflammatory responses   ↔   Inflammatory infiltrates  
Antioxidant properties   ↔   Increase oxidative damage  
Antithrombotic properties  ↔   Upregulates platelet adhesion 
Antifibrotic effects   ↔   Increasing atrial fibrosis 
Figure 1 Atrial fibrillation and pleiotropic effect of statins. Vascular Health and Risk Management 2009:5 536
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AF.34,43 Statins as well as angiotensin-converting enzyme 
inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) 
have the potential to modulate inflammatory pathways5,6 and 
could therefore reduce the susceptibility to AF after ablation 
in general and attenuate the acute inflammatory response in 
the early post ablation period .
Furthermore, CRP-lowering with atorvastatin appears to be 
effective in eliminating paroxysmal atrial fibrillation (PAF) dur-
ing daily life in a significant proportion of patients. In a prospec-
tive study45 on 80 patients with proven PAF, 40 patients were 
randomized to placebo (placebo group) and 40 to atorvastatin 
(treatment group). Plasma CRP levels and ambulatory monitor-
ing were repeated after four to six months of therapy. The two 
groups were comparable with respect to baseline characteristics, 
number of episodes of PAF, and baseline plasma CRP levels. 
The treatment group had lower median CRP levels exhibited 
a highly significant reduction in PAF (p  0.001). Paroxysmal 
AF was completely resolved in 26 (65%) of 40 patients in the 
treatment group versus four (10%) of 40 in the placebo group. 
By logistic regression, treatment with atorvastatin was an 
independent predictor of PAF resolution.
As another inflammatory marker associated with AF, IL-6 
is a pleiotropic cytokine that has diverse physiological roles, 
including mediation of both pro-inflammatory responses 
and cyto-protective functions. There have been few studies 
that have investigated the relationship between IL-6 and AF 
and shown significant correlation.47
TNF-α is a cytokine that plays a significant role in the ini-
tial activation of the immune system. Its release is stimulated 
by several factors, including IL-1β and bacterial endotoxin. 
Intra-arterial TNF-α causes an acute local vascular inflamma-
tion that is associated with impaired endothelium-dependent 
relaxation. So far, there has been few studies that have looked 
into the possible association between TNF-α and AF. These 
were very small studies and did not adjust for confounding 
factors; however, they demonstrated increased levels of 
TNF-α in patients with AF compared with healthy controls 
in sinus rhythm.38,41 Going into the details of these studies is 
beyond the scope of this article.
Finally, a relationship between elevated white blood cell 
count as a marker of inflammation and the development of AF 
after cardiac surgery has been shown in 181 consecutive patients 
undergoing coronary bypass or cardiac valve surgery.48
Pleiotropic effects of statins
The beneficial effects of statins on AF, beyond cholesterol 
lowering, have been reported in several studies, including 
improvement of endothelial dysfunction, increased nitric 
oxide (NO) bioavailability, antioxidant properties, inhibition 
of inflammatory responses, stabilization of atherosclerotic 
plaques, and antithrombotic properties (Figure 1).13,49–52 
Statins are known to lower the levels of acute-phase proteins 
independently of their effects on cholesterol.8,53,54 Also the 
antifibrotic effects, modulation of matrix metalloproteinases, 
interaction with peroxisome receptors that regulate prolif-
eration, and endothelial NO synthase protect atrial myo-
cardium during ischemia. For these reasons, statins may be 
able to decelerate or even reverse structural remodeling in 
patients with AF. Additionally, pre-treatment with high-dose 
atorvastatin prevented electrical remodeling in a pericarditis 
dog model and high-dose simvastatin attenuated down regu-
lation of calcium channel subunits, preventing shortening of 
atrial refractoriness, a central element of electrical remodel-
ing in AF. However, this sounds familiar: positive effects on 
intracellular calcium handling and atrial electrical remodeling 
have also been reported in animal studies with verapamil, 
but, in clinical trials this drug was unable to prevent atrial 
electrical remodeling and recurrence of AF.13,28,49–51,55–60
A recent study by Marín and colleagues13 found statin 
use was significantly associated with a decreased incidence 
of postoperative AF and an increased tissue inhibitor matrix 
metalloproteinase-1/matrix metalloproteinase-1 ratio in 
patients undergoing coronary artery bypass grafting (CABG). 
Recent data have suggested that statins can improve the 
sympathetic vagal balance in heart failure. One study showed 
that simvastatin could normalize sympathetic outflow and 
cardiovascular reflex regulation and restore the sympatho-
vagal balance in rabbits with pacing-induced congestive heart 
failure (CHF). Furthermore another study demonstrated its 
beneficial effect on autonomic function in CHF by downregu-
lating central Ang II and superoxide mechanisms. Therefore, 
the autonomic modulation effects of statins may favorably 
prevent AF after CABG.61,62
More recently the effect of statins on collagen type I 
degradation and CRP in patients with CAD and AF has been 
shown in a study of 106 patients with CAD and AF: 40 (36 
men, mean age 72 ± 8 years) treated with a statin and 66 
(48 men, mean age 74 ± 9 years) not treated with a statin. 
Serum concentrations of carboxy-terminal telopeptide of 
collagen type I, an index of collagen type I degradation, and 
hs-CRP were measured. Carboxy-terminal telopeptide of 
collagen type I levels were significantly higher (p  0.001) 
in statin-treated patients (0.64 ng/ml, 95% CI: 0.57–0.71) 
compared with nonstatin-treated patients (0.38 ng/ml, 
95% CI: 0.31–0.44). These changes were independent of 
cholesterol levels (before or after therapy). Statin-treated Vascular Health and Risk Management 2009:5 537
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patients had significantly lower (p  0.001) CRP levels 
(0.25 mg/dl, 95% CI: 0.23–0.28) compared to statin nonusers 
(1.1 mg/dl, 95% CI: 0.92–1.25). Thus therapy with statins 
in patients with CAD and AF is associated with an increase 
in collagen degradation and an attenuation of inflammation, 
independently of cholesterol lowering.63
The effect of statins on endothelial function has been 
demonstrated in several studies which concluded that 
cholesterol levels even in the normal range may be inversely 
related to endothelium-dependent vasodilation, and this 
finding has important clinical implications. This suggests 
that lowering cholesterol levels even when it is within the 
normal range may improve the production and release of 
endothelium-dependent NO and hence improve endothelial 
function This idea is supported by recent reports that low-
ering cholesterol levels enhances endothelium-dependent 
vasodilation not only in subjects with massively elevated 
cholesterol levels but also in those with normal cholesterol 
levels. It is worth noting that lowering of average cholesterol 
levels in patients with documented CAD leads to decreased 
rates of myocardial infarction, and this protective effect may 
in part be due to improvement in endothelial function.52 The 
beneficial effects of statins are now recognized to extend well 
beyond their lipid-lowering properties. Through a combina-
tion of both distinct and interdependent effects on endothelial 
cell Rho GTPase regulation, NAPDH oxidase activity, NO 
bioavailability, and differential gene expression statins confer 
significant protection of the vasculature. Abundant in vitro 
data in addition to myriad reports relying on a range of animal 
models now firmly support the idea that these drugs may 
serve as novel and effective therapeutic agents in a variety 
of disease states characterized by vascular dysfunction.64
Statins and AF in the experimental 
studies
Supportive data from two studies demonstrate the efficacy 
of statins to reduce the burden of AF in animal models 
(Table 1). Kumagai and colleagues59 operatively induced 
sterile pericarditis in 20 dogs randomized to treatment with 
or without atorvastatin 2 mg/(kg/day) (commenced one week 
prior to operation). Atorvastatin reduces both the incidence 
of AF and the levels of hs-CRP compared with the control 
Table 1 Experimental studies on the effect of statins on atrial fibrillation
Author Study type Study result
Tsai et al19 Rats infused long term with Ang ii  
exhibited higher levels of activated Rac1, 
phospho-STAT3, collagen synthesis,  
and atrial fibrosis.
Oral losartan and simvastatin attenuated  
these effects
Chello et al21 experiments on right atrial segments 
obtained before the onset of 
cardiopulmonary bypass in two groups  
of patients. in chronic AF or sinus  
rhythm in either presence or absence  
of 5 µm simvastatin
Chronic AF upregulates CD40 expression + 
platelet adhesion to the endocardium. 
Simvastatin is effective in modulating this 
expression
Shiroshita-Takeshita et al66 experimental dogs were subjected  
to two-week VTP in the absence and 
presence of simvastatin (20 or 80 mg/day) 
or fenofibrate. Simvastatin vs. fenofibrate  
on CHF-related atrial remodeling.
Simvastatin prevented VTP-induced DAF 
and attenuated CHF-induced conduction 
abnormalities, atrial fibrosis and attenuated 
VTP-induced left-ventricular nitric-oxide 
synthase and nitrotyrosine increases, along 
with hemodynamic dysfunction and 
significantly attenuate TGF-β1-stimulated 
alpha-smooth muscle actin (alpha-SMA) 
expression
Kumagai et al59 Twenty dogs with sterile pericarditis model 
given atorvastatin orally (2 mg/kg/day)
On the second postoperative day, the 
atorvastatin group had a lower CRP level  
(7.6 ± 0.5 vs. 11.7 ± 1.3)
Shiroshita-Takeshita et al28 Dogs subjected to   ATP at 400 bpm  
in the absence and presence of treatment 
with simvastatin, vitamin C, and combined 
vitamins C and e.
Simvastatin attenuates AF promotion by atrial 
tachycardia in dogs, an effect not shared by 
antioxidant vitamins
Abbreviations:   AF, atrial fibrillation;   ATP, atrial tachypacing; CHF, coronary heart failure; CRP, C-reactive protein; DAF, pacing-induced  AF;   TGF-β1, transforming growth 
factor-β1;   VTP, ventricular tachypacing  AF.Vascular Health and Risk Management 2009:5 538
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group, which suggests that atorvastatin reduced the burden of 
AF by reducing the inflammatory substrate. In addition, these 
findings were shown to correlate with a lower percentage of 
fibrosis in all atrial regions in the atorvastatin group com-
pared with the placebo group. It was particularly interesting 
that the authors noted the greater difficulty of inducing AF 
before versus after the induction of pericarditis, which would 
support the influence of inflammation in AF generation. 
Another study65 showed that atorvastatin attenuates atrial 
oxidative stress and prevents atrial electrical and structural 
remodeling in rat hypertensive heart failure (HF) induced by 
chronic inhibition of NO synthesis.
Statin-induced inhibition of profibrotic atrial fibroblast 
responses and attenuation of left-ventricular dysfunction 
may contribute to preventing the CHF-induced fibrotic 
AF substrate, simvastatin, but not fenofibrate attenuated 
CHF-induced atrial structural remodeling and AF promotion. 
This had been found in an animal study done on dogs. 
Simvastatin prevented ventricular tachypacing-induced 
(VTP) pacing-induced AF (DAF) increases (147 ± 37 and 
84 ± 37 s at 20 and 80 mg/day, respectively), but fenofibrate 
did not (1018 ± 352 s). Simvastatin also attenuated 
CHF-induced conduction abnormalities (heterogeneity-index 
reduced from 1.5 ± 0.1 to 1.1 ± 0.1 and 1.0 ± 0.1 at 20 and 
80 mg/day; p  0.01) and atrial fibrosis (from 19.4 ± 1.3% to 
10.8 ± 0.8% and 9.9 ± 0.8% at 20 and 80 mg/day; p  0.01), 
while fenofibrate did not. Simvastatin (but not fenofibrate) 
also attenuated VTP-induced left-ventricular nitric-oxide 
synthase and nitrotyrosine increases, along with hemody-
namic dysfunction. Atrial fibroblast proliferation increased 
with 24-h fetal bovine serum (FBS) stimulation from 
654 ± 153 to 7264 ± 1636 DPM (p  0.001). Simvastatin, 
but not fenofibrate, suppressed fibroblast proliferation 
(664 ± 192 DPM; p  0.001). Simvastatin also signifi-
cantly attenuated transforming growth factor-β1-stimulated 
α-smooth muscle actin (α-SMA) expression (indicating 
myofibroblast differentiation) from 1.3 ± 0.1 to 1.0 ± 0.1 
times baseline (p  0.05).66 In another study by the same 
authors. 39 dogs subjected to rapid atrial tachypacing in 
the absence and presence of treatment with simvastatin 
(and vitamins C and E) had no effect. The investigators were 
able to demonstrate that, compared with controls, simvastatin 
reduced the promotion of AF following tachypacing.28
Statins and AF in the randomized 
trials and meta-analyses
Several randomized clinical trials (RCTs) and large 
observational studies have shown similar results on the 
beneficial effect of statins in AF, but no benefit was found 
in six RCTs and 10 observational studies with 7041 patients. 
The analysis of RCTs showed no significant effect of statins 
on AF development (relative risk [RR] 0.76, 95% CI: 
0.55–1.05; p = 0.09), with significant heterogeneity between 
individual studies (p = 0.0008, I(2) = 74.0%). Subgroup 
analysis revealed that differences in AF detection method-
ology may be the cause of heterogeneity. The analysis of 
observational studies demonstrated that statin use reduced the 
relative risk for AF by 23% (95% CI: 0.70–0.85, Z = 4.95; 
p  0.00001) without significant differences between 
the trials (p = 0.08). This favorable effect was greatest in 
the postoperative patients (RR 0.61, 95% CI: 0.49–0.76, 
Z = 4.30; p  0.0001).67
In six studies with 3,557 patients, three investigated the 
use of statins in patients with paroxysmal AF (one) or persis-
tent AF undergoing electrical cardioversion (two), and three 
investigated the use of statins in primary prevention of AF in 
patients undergoing cardiac surgery or after acute coronary 
syndrome (ACS). Statins were significantly associated with 
a decreased risk of AF compared with control (OR 0.39, 95% 
CI: 0.18–0.85; p = 0.02). The benefit of statin therapy seemed 
more marked in secondary prevention of AF (OR 0.33, 95% 
CI: 0.10–1.03; p = 0.06) than for new-onset or postoperative 
AF (OR 0.60, 95% CI: 0.27–1.37; p = 0.23).68
In a randomized comparison of 14 trials reporting the 
results of 15 unique analyses (n = 7402), there was a 20% 
incidence rate for any AF with varying rates depending on 
AF type (new-onset [11%], recurrent [56%], recurrent after 
cardioversion [54%], or postoperative [22%]). The use of a 
statin reduced the odds of developing any AF by 45% (OR 
0.55; 95% CI: 0.43–0.70); Q statistic; p = 0.001). Statins 
reduced the odds of developing new-onset AF by 32% (OR 
0.68; 95% CI: 0.51–0.90), recurrent AF by 57% (OR 0.43; 
95% CI: 0.24–0.79), recurrent AF after cardioversion by 
42% (OR 0.58; 95% CI: 0.32–1.05) and postoperative AF 
by 58% (OR 0.42; 95% CI: 0.27–0.65).69 Randomized com-
parison among 8659 patients in two large, randomized trials, 
PROVE IT-TIMI 22 and phase Z of the A to Z trial found 
that higher-dose statin therapy did not reduce the short term 
incidence of AF among patients after ACS when compared 
with standard dose statin treatment, during the two years of 
follow-up. Neither study showed a decreased AF risk with 
higher-dose statin. In PROVE IT-TIMI 22, 2.9% versus 3.3% 
in the high- versus standard-dose statin therapy, respectively, 
experienced the onset of AF over two years (OR 0.86, 95% 
CI: 0.61–1.23; p = 0.41). In A to Z, rates were 1.6% versus 
0.99%, respectively (OR 1.58, 95% CI: 0.92–2.70; p = 0.096). Vascular Health and Risk Management 2009:5 539
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In both trials, CRP levels (plasma or serum) tended to be 
higher among patients experiencing the onset of AF.70
Another large cohort included 13,783 patients.71 The 
primary outcome was time to development of AF. Propen-
sity scores were used to balance statin-treated and untreated 
patients with respect to baseline characteristics. Time 
from the initial visit to development of AF was analyzed 
with a Cox regression model, using statin treatment as a 
time-varying covariate. Among the 13,783 patients, 5417 
(39%) received statin treatment. Statin-treated patients were 
younger with fewer co morbid conditions. After propensity 
adjustment, the baseline characteristics of the statin-treated 
and untreated patients were similar. During an average 
follow-up of 4.8 years, 1979 (14%) patients developed AF. 
In the overall study population there was no difference in 
AF incidence with statin treatment (hazard ratio [HR] 1.0, 
95% CI: 0.88–1.14; p = 0.09). However, AF was less com-
mon among statin-treated patients with CHF (HR 0.57, 95% 
CI: 0.33–1.00; p = 0.04). No effects of statin treatment on AF 
incidence was found in patients with CAD.71 In the largest 
study so far,72 performed a cross-sectional analysis of 25,000 
patients enrolled in the multicenter Guidant-sponsored 
Advancement Heart Failure Registry; of these patients, 
7027 patients (27%) developed AF, and statin therapy led 
to a 23% reduction in AF, when compared with those not 
treated, even after multivariate analysis (OR for AF 0.685; 
p = 0.001) (Table 2).
Role of statins in primary AF-  
and CAD-associated AF
The role of statins and inflammation in primary AF are sum-
marized in Table 3 and others have been analyzed above. The 
effect of statins on the incidence of new-onset AF in patients 
presenting with suspicion of ACS has been explored in 1,526 
patients. 164 (10.8%) had new-onset AF and 601 (39.4%) 
were on a statin on admission. In univariate analysis and 
after correcting for age, race, diabetes mellitus, chest pain, 
and use of ACE-I, patients on statins were significantly less 
likely to have new-onset AF (OR 0.40, 95% CI: 0.33–0.69; 
p  0.01). This relation persisted in the multivariate model 
(OR 0.57, 95% CI: 0.39–0.83; p  0.01). In conclusion, 
patients presenting with suspicion of ACS were much less 
likely to have new onset AF if they were on a statin at time 
of presentation.73
Use of statins in patients with chronic stable CAD appears 
to be protective against AF. The underlying mechanism for 
this effect is unknown but appears to be independent of the 
reduction in serum cholesterol levels.11 This association 
between statin use and the risk of developing AF were 
examined univariately and with adjustment for potential 
confounding factors in 449 patients with CAD between the 
ages of 40 and 87 years who were followed for an average of 
five years. 52 patients (12%) developed AF during follow-up. 
Statin therapy was used by 59% of the patients during the 
study period and was associated with a significantly reduced 
risk of developing AF (crude OR 0.48, 95% CI: 0.28–0.83). 
This association remained significant after adjustment for 
potential confounders, including age, hypertension, left 
ventricular systolic function, occurrence of heart failure or 
acute ischemic events, and baseline cholesterol and changes 
in cholesterol levels (adjusted OR 0.37, 95% CI: 0.18–0.76). 
β-blocker use was significantly higher in the statin user group 
(80% vs. 67%; p = 0.02), but was not included in the final 
multivariable model. Again, the possibility of an interaction 
between statins and β-blockers was not reported in this obser-
vational study, thus it is possible that the observed reduction 
in AF may have been mediated by the higher β-blocker use 
in the statin group.
AF after cardioversion
In clinical studies, statins were considered effective in pre-
venting AF after electrical cardioversion. Several studies 
have evaluated this association. Nevertheless, controversial 
results have been published concerning the protective role 
of statins after electrical cardioversion. Some investigators 
found a significant decrease in arrhythmia recurrence with 
statins,12 and others did not.74 The number of studies on this 
subject is small and their sample sizes were limited; thus, 
data are insufficient, in our opinion, to recommend the use 
of statins before electrical cardioversion, and larger ran-
domized studies are needed to clarify this important topic. 
Siu and colleagues12 were the first to study the prevention 
of AF with statins. They retrospectively studied 62 patients 
with lone persistent AF lasting three months who underwent 
direct current cardioversion, and observed that statin-treated 
patients (n = 10) had less recurrent AF than the control group 
of 52 patients (40 vs 84%; p = 0.0007); however, this was 
a very small and under-powered observational study, In 
another study on 106 patients with a history of symptomatic 
AF lasting less than one day (age 63 ± 14 years, mean ± 
standard deviation [SD]) hs-CRP level determined prior to 
cardioversion represented an independent predictor of both 
successful cardioversion for AF and the maintenance of SR 
after conversion (Table 3).75
In a retrospective review of 625 patients with new 
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Table 2 Result from major randomized trials and meta-analyses
Author Meta-analyses Study types Conclusion
Fauchier et al68 Six studies with 3,557 patients Three studies investigated the 
use of statins in patients with PAF 
(1) or persistent AF undergoing 
electrical cardioversion (2), and three 
investigated the use of statins in 
primary prevention of AF in cardiac 
surgery patients or after ACS
Statins were significantly associated 
with a decreased risk of  AF 
compared with control (p = 0.02). 
Benefit of statin therapy seemed 
more marked in secondary 
prevention of AF (p = 0.06) than  
for new-onset or postoperative  
AF (p = 0.23).
Liu et al67 Six RCTs and 10 observational 
studies
7,041 patients No significant effect of statins on 
AF development (RR = 0.76, 95% 
CI:0.55-1.05; p = 0.09) observational 
studies showed statin use ↓ the 
relative risk for AF by 23%.   This effect 
was greatest in the post-operative 
patients (RR = 0.61, 95% Ci: 0.49–0.76)
Liakopoulos109 Three RCT (randomized 
prospective clinical trials), 
16 observational studies
31,725 cardiac surgery patients Preoperative statin therapy resulted 
in a 1.5% absolute risk reduction (2.2 
vs 3.7%; P  0.0001) and 43% odds 
reduction for early all-cause mortality 
(OR 0.57; 95% CI: 0.49–0.67).
Patel et al69 Fourteen trials reporting the 
results of 15 unique analyses
7,402 patients on statin therapy vs. 
nonstatins
Statin ↓ any AF by 45% (Q statistic 
p = 0.001). Statins ↓ new-onset AF 
by 32% (OR 0.68; 95% CI: 0.51–0.90), 
recurrent AF by 57% (OR 0.43; 95% 
Ci: 0.24–0.79), recurrent AF after 
cardioversion by 42% (OR 0.58; 95% 
Ci: 0.32–1.05) and postoperative AF 
by 58% (OR 0.42; 95% CI: 0.27–0.65).
Author Randomized trials Study types Conclusion
McLean et al70 Two large, randomized trials: 
PROVe iT-TiMi 22 and phase Z  
of the A to Z trial,
Low- vs. high-dose statin therapy to 
evaluate whether higher-intensity 
statin therapy ↓ the risk of AF onset 
at two-years follow-up
Neither study showed ↓ AF risk 
with higher-dose statin. in PROVe 
iT-TiMi 22, 2.9% versus 3.3% in the 
high- versus standard-dose statin, 
respectively, in both trials, C-reactive 
protein levels (plasma or serum) 
tended to be higher among patients 
experiencing the onset of AF
Coletta et al97 GISSI-HF trial: a randomized, 
double-blind, placebo-controlled 
trial,
7046 patients with clinical evidence 
of HF of any cause, median followed 
up at 3⋅9 years
Rosuvastatin 10 mg daily did not 
affect clinical outcomes in patients 
with chronic heart failure of any 
cause (p = 0.943)
Hanna et al95 Data from ADVANCeNT(SM), a 
multicenter registry
25,268 patients with reduced  
LVeF  40%
in multivariable analysis, lipid-
lowering drug use remained 
significantly associated with reduced 
odds of   AF (OR [OR] 0.69, 95% Ci: 
[Ci] 0.64–0.74),
Dickinson et al96 SCD-HeFT study of followed up of 
median of 45.5 months.
2521 functional class ii and iii HF 
patients with LVeF  35%, ischemic 
and nonischemic CM
Mortality risk significantly lower in 
those taking a statin (HR [95% Ci], 
0.70 [0.58–0.83]). in all subgroups: 
ischemic CM(0.69 [0.56–0.86]), and 
nonischemic CM(0.67 [0.47–0.96]), 
iCD (0.66 [0.46–0.95], noniCD  
(0.71 [0.57–0.87]), NYHA ii  
(0.62 [0.48–0.79]), NYHA iii  
(0.79 [0.61–1.03]).
(Continued)Vascular Health and Risk Management 2009:5 541
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prospectively in the multicenter Canadian Registry of AF 
(CARAF) trial, logistic regression was used to model the 
effect of statin use on the recurrence of AF at one year while 
adjusting for potential confounders including concurrent 
medications. In a predominantly male population (62%) 
with median age 63 years, 12.3% were on statins at baseline. 
Overall, 32.5% had documented recurrence of AF at one year; 
23.4% in patients on statins compared to 33.8% in those not 
on statins (p = 0.07). After adjustment for baseline differences 
and concomitant β-blocker use, statin use was associated with 
a 74% reduction in AF recurrence, but only in statin users on 
β-blockers (OR 0.26, 95% CI: 0.10–0.66); statin users not on 
β-blockers (OR 1.07, 95% CI: 0.44–2.58). While CARAF 
has limitations, it was not designed primarily to evaluate the 
effect of statins on recurrence of AF. Statin use was based 
on physician/patient choice, not random assignment, mak-
ing confounding by indication a concern. Nevertheless, it is 
unlikely that physicians recommended statin therapy based 
on likelihood of AF recurrence. Careful analyses showed that 
CARAF did not document the exact time of AF recurrence; 
instead, the study required electrocardiography-documented 
evidence of recurrence between scheduled annual visits. 
Therefore, Kaplan–Meier curves comparing the time course 
of recurrence could not be constructed. Baseline character-
istics varied significantly between the statin and nonstatin 
users, and it is possible that there were other unmeasured 
confounders. In statin users, older age, diabetes, hyperten-
sion, and larger left atrial size would be expected to increase 
the likelihood of AF recurrence. Conversely, statin users were 
more likely to be on rate- and rhythm-control medications, 
a bias that would tend to decrease the likelihood of recur-
rence. The study also had several strengths. First, the rigorous 
ascertainment of AF recurrence is unlikely to be biased by 
statin use because statin use was not a focus of the CARAF 
study, nor was the association between statin use and AF 
known at the time CARAF was enrolling patients. Second, 
the cohort comprises patients with newly diagnosed AF. By 
definition, these patients would not have been exposed to any 
prior rate- or rhythm-control strategies that might affect the 
likelihood of AF recurrence. Indeed, this is a unique feature 
and strength of the study.76
A prospective study77 assessed the role of CRP in 
predicting long-term risk of AF recurrence after electrical 
cardioversion in 102 patients (age 67 ± 11 years; 58 men) 
with nonvalvular persistent AF who underwent successful 
biphasic electrical cardioversion, had hs-CRP measured 
immediately before cardioversion, and were followed-up for 
one year. Patients were divided into four groups according to 
CRP quartiles. The four groups were similar in age, gender, 
ejection fraction, and left atrial size. Patients in the lowest 
CRP quartile (1.9 mg/L) had significantly lower rates of 
AF recurrence (4% vs. 33% at three months in the other three 
groups combined [p = 0.007] and 28% vs. 60% at one year 
[p = 0.01]). Survival analysis confirmed that patients in the 
lowest CRP quartile had a lower recurrence rate (p = 0.02). 
Cox regression analyses using age, gender, hypertension, 
diabetes, ejection fraction, left atrial diameter, use of antiar-
rhythmic drugs, ACE-Is or Ang II antagonists, and statins, 
and CRP quartiles as covariates showed that only CRP 
was independently associated with AF recurrence during 
follow-up (HR 4.98, 95% CI: 1.75–14.26; p = 0.003).
Additionally, atorvastatin was associated with a signifi-
cantly reduced risk of developing AF (unadjusted RR 0.23, 
95% CI: 0.064–0.82; p = 0.024). This association remained 
significant after adjustment for these predictors (adjusted RR 
0.19, 95% CI: 0.052–0.72; p = 0.01). At baseline, hs-CRP 
levels were not different between the two groups (p = 0.92). 
Although the hs-CRP levels decreased significantly 48 hours 
after electrical cardioversion compared with the baseline levels 
in group I (2.82 ± 1.46 vs. 2.56 ± 1.3 mg/dl; p = 0.02), no 
significant change occurred in group II (2.87 ± 0.8 vs. 2.84 ± 
0.8 mg/dl; p = 0.09).78 In contradiction, pravastatin did not 
reduce the recurrence rate of AF after electrical cardioversion 
in an open, controlled multicenter study. Patients (n = 114) 
who had AF  48 hours and who were scheduled for electrical 
cardioversion were randomized to receive 40 mg of pravastatin 
Table 2 (Continued)
Author Meta-analyses Study types Conclusion
Adabag et al71 Cohort: an average follow-up of 
4.8 years
13,783 patients, CAD patients No difference in AF incidence with 
statin treatment (p = 0.09). No 
effects of statin treatment on AF  
incidence in CHD patients; however, 
AF was reduced in a subset of 
patients with CHF (p = 0.04)
Abbreviations: AF,  atrial fibrillation; CAD, coronary artery disease;   ACS, acute coronary syndrome, CHF, coronary heart failure; PAF, paroxysmal atrial fibrillation; LVEF, 
left-ventricular ejection fraction.Vascular Health and Risk Management 2009:5 542
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once daily for thee weeks before and six weeks after electrical 
cardioversion or no drug in addition to standard therapy.74
Role of statins in postablation AF
Ablation-induced inflammatory activation and is supposed 
to contribute to the phenomenon of early AF recurrence.44 
Studies in this area are limited and have significant limita-
tions. In a retrospective study of 177 consecutive patients 
(mean age = 56 ± 11 yrs, 69% males) who underwent 
ablation for paroxysmal (132 patients) or persistent AF 
(45 patients), patients were treated with ACE-I (31 patients) 
or ARB (18 patients) or statins (50 patients) prior to ablation 
and follow-up of 13.8 ± 8.6 months. 72% of these patients 
were free of AF. Thirty-three of 50 (60%) of patients taking 
statins were free of AF, 17 of 31 (55%) were free from AF 
in the ACE-I-treated group, while 17 of 18 (94%) were free 
from AF in the ARB group. Using Cox regression analysis to 
correct for baseline variables, treatment with statins did not 
decrease the recurrence rate (HR 1.10, 95% CI: 0.55–2.27; 
p = 0.79) nor did treatment with renin–angiotensin system 
blockers (HR 0.94, 95% CI: 0.46–1.93; p = 0.87). However, 
subgroup analysis showed that treatment with ARB was asso-
ciated with a trend towards lower AF recurrence (HR 0.17, 
95% CI: 0.02–1.34; p = 0.09). However this is a retrospective 
and not randomized and there may be other genetic and envi-
ronmental factors that were not corrected for by multivariate 
analysis.79 The long duration of AF prior to ablation might 
account for the lack of efficacy of these medications since 
the patients are more likely to have established fibrosis and 
scarring, and thus less likely to respond to medications that 
inhibit inflammation and initial collagen deposition.
A study by Richter and colleagues80 included 234 patients 
(23–80 years; 71.8% men) with drug-resistant paroxysmal 
(n = 165) or persistent AF (n = 69) who either underwent a 
Lasso-guided segmental pulmonary vein isolation (n = 83) or 
a CARTO-guided left atrial circumferential ablation (n = 151), 
which definitely resulted in inflammation. Treatment with 
statins (n = 113), ACE-Is, or ARBs (n = 124), or a combina-
tion of a statin and an ACE-I or ARB (n = 75) was started 
three months before ablation and was continued during 
follow-up of 12.7 months, 64% of patients with paroxysmal 
and 45% of patients with persistent AF were free of AF. 
Statin use (HR 1.06; p = 0.79), ACE-I or ARB use (HR 1.12; 
p = 0.59), and their combined use (statin + ACE-I/ARB; 
HR 1.17; p = 0.54) did not significantly influence ablation 
outcome as assessed by Cox regression analysis. In addition, 
after multivariate adjustment for potential confounders, the 
examined drugs did not significantly affect ablation outcome. 
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Ablation induced an acute upregulation of CRP levels 
(preablation vs. 48 hours postablation, 5.9 F 8.1 vs. 33.7 F 
30 mg/L; p = -0.001) and other inflammatory markers. The 
examined drugs did not significantly alter baseline levels 
or ablation-induced upregulation of inflammatory markers. 
However this study was a retrospective analysis of prospec-
tively gathered data and hence is subject to the limitations 
inherent in any retrospective study. A possible limitation of 
this study is that AF-free follow up included a proportion of 
patients continued on previously ineffective antiarrhythmic 
drugs reflecting a rather conservative strategy of withdrawal 
of antiarrhythmic drugs after ablation. So far further studies 
are needed to clarify this aspect.
Role of statins in AF 
after pacemaker implantation
Recently and till the time of writing this review, few studies 
have evaluated the role of statins in AF after pacemaker 
implantation. The predictors of atrial tachyarrhythmia (AT)/
AF recurrence in pacemaker implanted patients with sinus 
node disease were evaluated in prospective observational 
cohort study on 185 patients.81 The time to first AT/AF 
recurrence and AT/AF burden (h/day) was retrieved at each 
follow-up visit by pacemaker interrogation. AT/AF recurred 
following pacemaker implantation in 157 (85%) patients. At 
one year of follow-up, patients without recurrence were more 
likely to be on statin therapy (54%) when compared with 
patients without statin therapy (25%, x = 12.31; p = 0.0004). 
Statin therapy was the only significant predictor of AT/AF 
recurrence in a multivariate logistic regression model 
(adjusted OR 0.33, 95% CI: 0.14–0.74; p = 0.007). AT/AF 
burden was significantly lower in the group on statin therapy 
(median 0.10 h/day) when compared with the no statin group 
(median 0.39 h/day; p = 0.0059).
The Atorvastatin Trial for Atrial High Rate Episodes 
in Patients with Bradycardia (ATAHEB) was a prospec-
tive, randomized, and open-label study designed to test the 
efficacy of atorvastatin in preventing the occurrence of atrial 
high-rate episodes (AHE) or AF episodes in patients with a 
pacemaker. Fifty-two patients (23 males, 70 ± 13 years old) 
were randomized to the statin group (atorvastatin 20 mg/
d) and 54 (25 males, 72 ± 13 years old) to the nonstatin 
group. Event-free survivals from AHE  1 minute were 
not significantly different between the two groups (log-rank 
P = 0.410). However, patients in the nonstatin group were 
more likely to develop AHE  10 minutes than those in 
the statin group (log-rank p = 0.028). AHE  10 minutes 
occurred in three (5.8%) of 51 patients in the statin group 
after one year of follow-up, and 10 (19.2%) of 52 patients 
(OR 0.26; p = 0.041) in the nonstatin group. Interestingly the 
mean left atrial volume of the statin group was significantly 
lower than that of the nonstatin group at the end of follow-up 
(39.7 ± 1.7 vs. 43.7 ± 1.9 mL; p = 0.0001). However there are 
limitations to this study. First, this is a small randomized, but 
not placebo-controlled, study. The sample size is relatively 
small. But the pacemaker interrogation is more sensitive than 
the Holter ECG monitoring or symptom-based screening and 
thus substantially decreased the case number needed to find 
a significant result.82
In a cohort of 264 patients (49% women, mean age 
[± SD] 71 ± 12 years) with permanent pacemakers who 
are at high risk for AF. 36% had CAD. AF developed in 
70 patients (26%) at a median of 359 days post-pacemaker 
implantation. The incidence rate for the first occurrence of 
AF post-pacemaker implantation among patients treated 
and not treated with statins was 10.5 versus 9.8 events per 
100 patient-years, respectively (p = 0.81). Even after con-
trolling for baseline differences, the HR for developing AF 
among statin users did not achieve statistical significance 
(HR 0.59, 95% CI: 0.31–1.12). Concluding that statin therapy 
had no protective effect against the risk of AF in patients with 
permanent pacemaker. The low prevalence of CAD in these 
patients may partly explain the results of this study.83
Another interesting study, in a large heterogeneous 
implantable cardioverter defibrillators (ICD) cohort, pro-
spectively followed, 1,445 patients receiving an ICD for the 
primary (n = 833) or secondary (n = 612) prevention. with 
follow-up (mean ± SD) 874 ± 805 days. Overall, 745 patients 
received statin therapy and 700 did not. Outcome measures 
include incidence of AF/atrial flutter (AFL) that initiated 
ICD therapy or was detected during ICD interrogation. 
Cox hazard regression analyses conducted to determine 
the predictors of AF/AFL with and without inappropriate 
shock delivery excluding inappropriate shocks resulting 
from lead dysfunction or other exogenous factors. There 
were 563 episodes of AF/AFL detected, with 200 episodes 
resulting in inappropriate shock therapy. The use of statin 
therapy was associated with an adjusted HR of 0.472 (95% 
CI: 0.349–0.638; p  0.001] for the development of AF/AFL 
with shock therapy and 0.613 (95% CI: 0.496–0.758; 
p  0.001) without shock therapy when compared with the 
group without statin use (Table 3).84
AF in left ventricular dysfunction
The antiarrhythmic mechanisms of statins regarding AF 
prevention in patients with HF are still not clear. One possible Vascular Health and Risk Management 2009:5 546
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pathway involves inflammation and oxidative stress. Recent 
studies have demonstrated the implication of inflammation 
and oxidative stress in the pathophysiology of AF11,67,85,86 and 
HF.87 Several pharmacological approaches with nonchannel 
blocking drugs that have anti-inflammatory and antioxidant 
effects have shown beneficial effects on AF.88,89 Furthermore, 
statin treatment has been associated with a significant clinical 
improvement in patients with HF along with a reduction in 
inflammatory biomarkers, statin use was associated with reduced 
mortality and hospitalization in patients with HF of ischemic 
and nonischemic HF patients equally.90,91 Besides the presumed 
anti-inflammatory and antioxidant effects of statins in AF92 
some additional mechanisms have also been suggested, these 
include anti-ischemic effects, attenuation of atrial remodeling, 
ion channel stabilization, improvement in endothelial function, 
and modulation of the autonomic nervous system.60,67,93,94
As mentioned above, two experimental studies have 
evaluated the role of statin treatment in animal models of 
HF. Firstly, Shiroshita-Takeshita and colleagues66 have 
demonstrated that simvastatin effectively attenuates atrial 
structural remodeling and AF promotion in a dog model of 
tachy-cardiomyopathy. Furthermore, Okazaki and colleagues65 
showed that atorvastatin attenuates atrial oxidative stress and 
prevents atrial electrical and structural remodeling in rat hyper-
tensive HF induced by chronic inhibition of NO synthesis.
Very recently, clinical observational study added new 
evidence to this issue. In a large prospective cohort of 13,783 
patients with coronary heart disease, there was no difference 
in AF incidence between statin-treated and untreated patients 
during a follow-up of 4.8 years. Interestingly, subgroup analysis 
of patients with HF showed that recent statin treatment was 
associated with a 43% reduction in AF incidence71 Table 2.
In analysis of another two retrospective studies which 
evaluated the role of statins on AF prevention in patients with 
heart failure, the larger study was a cross-sectional study by 
Hanna and colleagues95 of 25,268 patients with left ventricular 
systolic dysfunction, enrolled in a multicenter registry 
(ADVANCENT). Only 25.3% of patients with prevalent 
AF used statins compared to 33.1% without AF (p = 0.001). 
Even after adjustment for concomitant drug use and comor-
bid conditions, the OR for AF in patients on statins was 0.69 
(0.64–0.74) compared to those who had not used statins. 
β-Blocker use in this cohort was quite high (79.1%) and the 
prevalence of AF was lower in those on β-blockers (26.5%) 
versus in those who were not (33.5%), but the authors did 
not report on the effect of concomitant statin and β-blocker 
use. Post hoc analysis from the Sudden Cardiac Death in 
Heart Failure Trial (SCDHeFT)96 demonstrated that, after 
adjusting for several confounding factors, statin use was 
independently associated with a significant reduction (28%) 
in the relative risk of AF or atrial flutter during a follow-up 
period of 45.5 months (Table 2).
GISSI-HF, a randomized, double-blind, placebo-
controlled trial in 326 cardiology and 31 internal medicine 
centers in Italy, enrolled patients with chronic heart failure 
of New York Heart Association class II–IV irrespective of 
cause and left ventricular ejection fraction, and randomly 
assigned to n-3 poly unsaturated fatty acids (PUFA) 1 g 
daily (n = 3494) or placebo (n = 3481) and followed-up for 
a median of 3⋅9 years. Primary endpoints were time to death, 
and time to death or admission to hospital for cardiovascular 
reasons. GISSI-HF concluded that a simple and safe treat-
ment with n-3 PUFA can provide a small beneficial advantage 
in terms of mortality and admission to hospital for cardiovas-
cular reasons in patients with heart failure. In the GISSI-HF 
sub-analyses of patients randomly assigned to rosuvastatin 
10 mg daily (n = 2285) or placebo (n = 2289) using primary 
endpoints of time to death, and time to death or admission to 
hospital for cardiovascular reasons, 657 (29%) patients died 
from any cause in the rosuvastatin group and 644 (28%) in 
the placebo group (adjusted HR 1.00, 95.5% CI: 0.898–1.122; 
p = 0.943), with a final conclusion that rosuvastatin 10 mg 
daily did not affect clinical outcomes in patients with chronic 
heart failure of any cause.97 Whether higher doses have dif-
ferent effects need to be clarified.
Role of statins in perioperative AF
AF is the most common postoperative arrhythmia with sig-
nificant consequences on patient health. Postoperative AF 
complicates up to 8% of all noncardiac surgeries, between 
3% and 30% of thoracic surgeries, and between 16% and 
46% of cardiac surgeries. It increases morbidity and prolongs 
hospital stay. Advanced age is associated with degenerative 
and inflammatory modifications in atrial anatomy (dilation, 
fibrosis), which cause alterations in atrial electrophysiological 
properties (shortness of effective refractory period, dispersion 
of refractoriness and conduction, abnormal automaticity, and 
anisotropic conduction). which act as potential substrates for 
postoperative AF.98,99 Inflammation associated with cardio-
surgical procedures, together with catecholamine release, 
was suggested as having a pivotal role in postoperative AF 
reported that patients who developed AF after major thoracic 
surgery had a nearly two fold increase in postoperative CRP 
levels in comparison to control subjects.13,100,101 Statins exert 
several actions in cardiothoracic surgical procedures in 
addition to lipid-lowering. In patients undergoing CABG, Vascular Health and Risk Management 2009:5 547
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statins improve bypass graft potency, perioperative as well 
as long-term mortality rates. In addition, statins reduce the 
number of postoperative complications and clinical events, 
revascularization rates and postoperative hospital stay. 
Furthermore, they are protective against de novo AF and 
renal dysfunction following CABG. The preoperative use of 
statins has been related to a three-fold decrease in the odds 
of AF after noncardiac major thoracic surgery.51 A recent 
meta-analysis of 14 statin trials, with 7,402 patients, found 
that statins reduced the odds of developing postoperative AF 
by 58% (Table 2).69
During the past few years, the association between statin 
use and development of AF has been examined in different 
clinical settings. Recent meta-analysis on this issue showed 
different results between RCTs and observational studies, 
suggesting that statins may be effective in prevention of 
postoperative AF.102,67 In a prospective study which examines 
the relation between inflammation associated parameters to 
post-cardiac surgery. A single post-CABG cTnI measurement 
was assessed in 156 patients. Cardiac troponin-I levels were 
significantly higher in patients not preoperatively treated with 
statins (21.6 ± 4.1 vs. 13.3 ± 0.9; p = 0.05), thus preoperative 
treatment with statins may be beneficial in reducing postop-
erative inflammatory response.103
A retrospective study104 of 680 consecutive patients 
undergoing CABG surgery and/or aortic valve replacement, 
Preoperative statin treatment and occurrence of postoperative 
AF were examined in a cohort comprised 623 patients. The 
statin-treated patients had a 27.1% incidence of postopera-
tive AF vs. 38.3% in the nonstatin group (adjusted OR 2.00; 
95% CI: 1.24 to 3.24; p = 0.004). Simvastatin (40 mg) and 
atorvastatin (40 mg) demonstrated the greatest effect on 
postoperative AF at 15.6% and 21.2%, respectively, versus 
nonstatins (respective adjusted ORs, 3.89 [p  0.0001] and 
2.76 [p = 0.012]). Intermediate-dose (20 mg) statins were also 
effective against AF, at 24.4% for simvastatin (adjusted OR, 
2.32; p = 0.004) and 26.4% for atorvastatin (adjusted OR, 
1.99, p = 0.047). Low-dose statins, simvastatin or atorvastatin 
(10 mg), did not influence postoperative AF (Table 3).
The beneficial effect of statins in CABG has been con-
firmed in two recent studies. In an observational cohort 
study105 of 2,497 adult patients who underwent isolated 
CABG. Similar perioperative mortality was found between 
matched pairs with statin therapy vs. nonstatin therapy, five 
(0.76%) and eight (1.2%) (p = 0.40), respectively. Cardiac, 
neurologic, renal, and respiratory morbidity, occurrence of 
AF, and length of hospital stay were similar between the 
matched pairs and among quintiles of propensity scores. 
But different result were obtained in another study with 
over a two-year period follow up, 405 consecutive patients 
underwent isolated CABG procedures. Preoperative statins 
were associated with a 42% reduction in risk of AF develop-
ment after CABG surgery (OR 0.58, 95% CI: 0.37 to 0.91; 
p = 0.017, while stratifying on the propensity score). No dif-
ferent effect of statins on AF was observed with respect to age 
groups ( or = 70 and 70 years) (interaction, p = 0.711).106 
Previous AF and nonuse of statins are significantly associated 
with AF after CABG. This was explored in 234 consecutive 
patients underwent CABG (173 men; 65 ± 9 years of age) in 
whom the occurrence of postoperative AF was monitored. 
In a subgroup of 66 patients, plasma levels of matrix metal-
loproteinase-1 (MMP-1), its inhibitor, tissue inhibitor matrix 
metalloproteinase-1 (TIMP-1; as indexes of extracellular 
matrix remodeling), and N-terminus pro-BNP (related to 
left ventricular function) at baseline and at 24 hours after 
surgery were measured, 66 (28.2%) developed postoperative 
AF. In multivariate analysis, previous AF was related to an 
increase in the development of AF (OR; 11.92, 95%, CI; 
2.37 to 59.98, p = 0.026), whereas statin use was related to 
a decrease in arrhythmia (OR 0.52, 95%; CI: 0.28 to 0.96; 
p = 0.038). A higher TIMP-1/MMP-1 ratio at 24 hours after 
surgery was present in those who did not develop postopera-
tive AF (p = 0.043). Statin use was associated with increased 
TIMP-1 levels and TIMP-1/MMP-1 ratio (p = 0.027 and 
0.036, respectively)13 (Table 3).
In a population with appreciable β-blocker and amioda-
rone use, adjunctive preoperative statin use was still associ-
ated with a 40% reduction in patients’ odds of developing 
post-cardiothoracic surgery AF. Patients undergoing car-
diothoracic surgery from the randomized, controlled Atrial 
Fibrillation Suppression Trials I, II, and III were evaluated 
in nested cohort evaluation. Overall, 331 patients (59.6%) 
received a statin preoperatively and 224 patients (40.4%) did 
not. The study population had an average age of 67.8 ± 8.6 
years, 77.1% were male, 14.6% had valve surgery, 6.1% had 
a history of AF, 12.6% had a history of heart failure, In total, 
174 patients (31.4%) developed post-cardiothoracic surgery 
AF. Upon multivariate logistic regression, statin use was 
associated with a reduction in post-cardiothoracic surgery 
AF (adjusted OR 0.60; 95% CI: 0.37–0.99). Higher intensity 
statin dosing (40 mg of atorvastatin or more) seemed to be 
associated with the greatest reductions in post-cardiothoracic 
surgery AF (OR 0.45; 95% CI: 0.21–0.99) (Table 3).107 
Again, in an observational study of 362 consecutive 
patients (267 on and 95 not on statin). Postoperative AF 
was less frequent and its duration was shorter in patients Vascular Health and Risk Management 2009:5 548
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with preoperative statin treatment compared to control 
(p = 0.03 and 0.0001, respectively). The Kaplan–Meier 
analysis showed the protective effect of statins against the 
risk of developing AF again (p = 0.01).108 This study is 
an observational study with a limitation. Meta-analysis of 
over 30,000 patients undergoing cardiac surgery including 
19 studies (three randomized prospective clinical trials), 
16 observational studies) with (n = 17 201; 54%) or without 
(n = 14 524; 46%) preoperative statin therapy. Outcomes 
analyzed included early all-cause mortality (30-day mortal-
ity), myocardial infarction (MI), AF, stroke and renal failure. 
Preoperative statin therapy resulted in a 1.5% absolute risk 
reduction (2.2 vs. 3.7%; p  0.0001) and 43% odds reduction 
for early all-cause mortality (OR 0.57; 95% CI: 0.49–0.67). 
A significant reduction (p  0.01) in statin pretreated 
patients was also observed for AF (24.9 vs. 29.3%; OR 0.67, 
95% CI: 0.51–0.88), stroke (2.1 vs. 2.9%, OR 0.74, 95% 
CI: 0.60–0.91) (Table 2).109
Recently, a prospective randomized study ARMYDA-3 
(Atorvastatin for Reduction of MYocardial Dysrhythmia 
After cardiac surgery) has demonstrated that treatment with 
atorvastatin 40 mg/day started seven days before elective 
cardiac surgery under cardiopulmonary bypass and con-
tinued in the postoperative period significantly reduced the 
occurrence of postoperative AF by 61%. This benefit was 
more evident in the patients undergoing CABG (OR 0.24). 
However, this study did not include patients undergoing 
off-pump cardiac surgery, which is currently the preferred 
method of surgery in many centers.110 However, there was 
a greater use of β-blockers in the treatment group. Though 
this is not significant in the formal statistical sense (p = 0.08), 
it is notably higher (72% vs. 60%). The authors do refer to 
the established role of β-blockade in the reduction of postop-
erative AF, and include it in their multivariate analysis, which 
is consider of particular relevance given the size of the study 
population (n = 200). Additionally, a nonsignificant excess 
of patients undergoing valve surgery in the placebo group 
(25% vs. 16%), which compared with nonvalvular surgery 
confers a greater likelihood of postoperative AF. whether 
this excess in valve surgery has been taken into account by 
the multivariate analysis is not clear.
The predisposing determinants of the development 
of AF after off-pump CABG surgery remain unclear. 
A prospectively designed study of patients undergoing elec-
tive off-pump CABG surgery showed that pretreatment with 
atorvastatin 20 mg/d, started three days before surgery, in 
patients undergoing elective off-pump CABG was beneficial 
in reducing the incidence of postoperative AF. The incidence 
of AF was significantly lower in the atorvastatin group than 
in the control group (13% vs. 27%; p = 0.04). Postoperative 
peak N-terminal pro-brain natriuretic peptide levels were 
significantly higher in the patients with AF (p = 0.03). Multi-
variate analysis identified pretreatment with atorvastatin as an 
independent factor associated with a significant reduction in 
postoperative AF (OR 0.34; p = 0.04). Higher postoperative 
peak N-terminus pro-B–type natriuretic peptide levels were 
associated with the development of postoperative AF (OR 
1.02 per 100 pg/mL; p = 0.03).111 this study demonstrate that 
a short-term pretreatment with atorvastatin results in a 66% 
risk reduction of postoperative AF that persists in patients 
undergoing off-pump CABG.
There is now an increasing body of evidence that inflam-
mation have pivotal role in the pathogenesis of postopera-
tive AF. Two recent studies have shown that inflammation 
can alter atrial conduction, facilitating re-entry and then 
predisposing to the development of postoperative AF.112,113 
It is well known that extracorporeal circulation is associ-
ated with systemic inflammatory response, which might 
be in part responsible for the occurrence of postoperative 
AF. Interestingly, it has been reported recently that the 
leukocytosis, which is usually encountered in the days after 
cardiopulmonary bypass, is an independent predictor for the 
occurrence of postoperative AF.48,114 Perioperative statin use 
has been associated with favorable postoperative outcome 
in both cardiovascular and noncardiovascular conditions, 
and has particular advantage in combination with β-blocker 
therapy. However, elucidating the impact of statin therapy 
on a specific clinical end-point would require a larger study 
population in order to generate a robust conclusion.
Conclusion
Despite a growing body of evidence to support a protective 
role of drugs with anti-inflammatory properties in AF as 
illustrated above, it should not be overlooked that there are 
also numerous studies that could not find a preventive effect 
on AF occurrence at all. Such conflicting data may in part be 
related to different study populations as well as differences 
in AF history and predisposing diseases. Furthermore, there 
was a great variance in study protocols that could contrib-
ute to controversial results. Among others, the sample size, 
follow-up duration, duration of drug application, drug dose 
used, and method to assess occurrence of AF varied widely. 
Moreover, a wide range of different substances have been 
examined. Especially in the case of statins, this could account 
for inconsistent results. Thus, there are preliminary data to 
support the potential utility of statins in the primary and Vascular Health and Risk Management 2009:5 549
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secondary prevention of AF. These observed positive effects 
of statins on the burden of AF appeared to be independent of 
their cholesterol reducing properties. However, further data 
from large-scale randomized trials are clearly needed.
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